T-Ray Science announces namechange to Verisante, and apparent move out of THz commercialization for now, at least

MY NOTE: consistent with what I  had previously posted on 1/13/11, T-Ray Science, has changed it's name, removing any doubt that it's current product platform is not based upon THz.  Good luck to Thomas Braun, and his newly named company Verisante, it's doubtful, you will see them on this blog again, unless there is a new product line based upon THz.

Press Release Source: T-Ray Science, Inc. On Monday January 17, 2011, 10:00 am EST

VANCOUVER, BRITISH COLUMBIA--(Marketwire - Jan. 17, 2011) - T-Ray Science, Inc. (TSX VENTURE:THZ - News; the "Company" or "T-Ray") announces that, at a Special Meeting of Shareholders held on January 13, 2011, shareholders approved a change of the name of the Company to Verisante Technology, Inc. ("Verisante").
Concurrently, the Company's URL has changed to http://www.verisante.com.
The common shares of the Company will commence trading on the TSX Venture Exchange on Tuesday January 18, 2011 under the trading symbol "VRS" and under CUSIP Number 92346G104.
"With the Company's full commitment towards commercialization of Verisante Aura(TM) for the early detection of skin cancer and Verisante Core(TM) for the early detection of lung cancer, the name Verisante Technology better reflects the Company's current focus and business model and seamlessly aligns the Company's brand with the products themselves," said Thomas Braun, President & CEO.
Shareholders holding shares in brokerage accounts or in street names will not need to take any action. Registered shareholders will be sent a Letter of Transmittal by the Company outlining the procedure to exchange their existing shares for shares evidencing the new name of the Company.
About Verisante
Verisante is a medical device company committed to commercializing innovative systems for the early detection of cancer. The Verisante Core(TM) series for lung cancer detection and the Verisante Aura(TM) for skin cancer detection utilize a proprietary cancer detection platform while the operating software and probe technology are unique to each device. The cancer detection platform was developed by the BC Cancer Agency and tested and refined at the Skin Care Centre at VGH. This exclusive platform technology allows Verisante to develop and offer a range of compact, non-invasive cancer detection devices that offer immediate results for many of the most common cancers, including gastro-intestinal, colorectal and cervical cancers.
About the BC Cancer Agency
The BC Cancer Agency, an agency of the Provincial Health Services Authority, is committed to reducing the incidence of cancer, reducing the mortality from cancer, and improving the quality of life of those living with cancer. It provides a comprehensive cancer control program for the people of British Columbia by working with community partners to deliver a range of oncology services, including prevention, early detection, diagnosis and treatment, research, education, supportive care, rehabilitation and palliative care. The BC Cancer Foundation raises funds to support research and enhancements to patient care at the BC Cancer Agency. www.bccancer.bc.ca
About The Skin Care Centre at Vancouver General Hospital
The Skin Care Centre at VGH is affiliated with the UBC Department of Dermatology and Skin Sciences. It is a national centre of excellence uniting clinical care, research, and education. The Centre sees over 20,000 patients annually in general and subspecialty dermatology clinics, and runs the country's busiest phototherapy centre. A critical component of the Skin Care Centre at VGH is its comprehensive and aggressive program dedicated to exploring all aspects of skin cancer, encompassing treatment, clinical, and basic science research. http://www.skincarecentre.ca/
Forward Looking Statements
This release contains forward-looking statements, including, but not limited to, statements regarding the future commercialization of medical devices, the market demand for these products and the proprietary protections the Company will obtain with regard to the technology, all of which statements are subject to market risks, and the possibility that the Company will not be able to obtain patent protection or obtain sufficient customer demand. These statements are made based upon current expectations and actual results may differ from those projected due to a number of risks and uncertainties